AN2 Therapeutics Announces Extension of Funding for TB Research Collaboration with GSK

28 September 2026

AN2 Therapeutics press release

AN2 Therapeutics, Inc. announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics’ research activities under its ongoing TB research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS) inhibitors for the treatment of TB.

Read the full press release here.

Source: AN2 Therapeutics, Inc.